Clinical Trial Update: A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium [Phase 2, Phase 3]

View source ↗

Summary

This document reports on a double-blind randomized trial of lapatinib versus placebo in metastatic bladder cancer (metastatic urothelial carcinoma), spanning Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: Queen Mary University of London | Conditions: Bladder Cancer | Phase 2, Phase 3 | Status: UNKNOWN